Zydus Cadila has received the final approval from the USFDA to market Esomeprazole Magnesium Delayed-Release Capsules USP (US RLD - NEXIUM), 25 mg and 40 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.
Esomeprazole belongs to the group of medicines termed as proton pump inhibitors. Esomeprazole reduces the amount of acid secreted by the stomach. It is used to treat the symptoms of gastroesophageal reflux disease, to reduce the risk of stomach ulcers in some people taking pain medicines, to treat patients with stomach infection (Helicobacter pylori) along with certain antibiotics and long-term treatment of conditions where stomach makes too much acid.
The group now has 266 approvals and has so far filed over 350 ANDAs since the commencement ofthe filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.251.1 as compared to the previous close of Rs. 244.55. The total number of shares traded during the day was 205776 in over 3503 trades.
The stock hit an intraday high of Rs. 253.9 and intraday low of 242.3. The net turnover during the day was Rs. 51063312.